A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

被引：0
|
作者：
Dinko Vitezic
机构：
[1] University of Rijeka Medical School,Clinical Pharmacology, Department of Pharmacology
[2] and Department for Science and Clinical Pharmacology,undefined
[3] University Hospital Centre Rijeka,undefined
来源：
Drug Safety | 2001年 / 24卷
关键词：
Erectile Dysfunction; Phentolamine; Priapism; Alprostadil; Intracavernosal Injection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Sildenafil is an oral treatment for erectile dysfunction (ED). It acts as an inhibitor of 3′,5′-cyclic guanosine monophosphate-phosphodiesterase type 5. An effective treatment for ED is required to produce an erectile response sufficient for satisfactory sexual performance. This has been documented for sildenafil in men with ED of differing aetiologies and baseline severity in various types of clinical trials.
引用
收藏
页码：255 / 265
页数：10
相关论文
共 50 条
  • [41] Sildenafil and erectile dysfunction
    A. Fabbri
    A. Aversa
    A. Isidori
    Journal of Endocrinological Investigation, 1999, 22 : 486 - 492
  • [42] RISK-BENEFIT ASSESSMENT OF AMIODARONE IN THE TREATMENT OF CARDIAC-ARRHYTHMIAS
    COUNIHAN, PJ
    MCKENNA, WJ
    DRUG SAFETY, 1990, 5 (04) : 286 - 304
  • [43] A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia
    Ekman, P
    DRUG SAFETY, 1998, 18 (03) : 161 - 170
  • [44] RISK-BENEFIT ASSESSMENT OF DRUGS USED FOR THE TREATMENT OF MENSTRUAL DISORDERS
    HIGHAM, JM
    SHAW, RW
    DRUG SAFETY, 1991, 6 (03) : 183 - 191
  • [45] Risk-benefit assessment of ivabradine in the treatment of chronic heart failure
    Urbanek, Irmina
    Kaczmarek, Krzysztof
    Cygankiewicz, Iwona
    Ptaszynski, Pawel
    DRUG HEALTHCARE AND PATIENT SAFETY, 2014, 6 : 47 - 54
  • [46] A RISK-BENEFIT ASSESSMENT OF MOCLOBEMIDE IN THE TREATMENT OF DEPRESSIVE-DISORDERS
    NORMAN, TR
    BURROWS, GD
    DRUG SAFETY, 1995, 12 (01) : 46 - 54
  • [47] A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease
    Samuels, SC
    Davis, KL
    DRUG SAFETY, 1997, 16 (01) : 66 - 77
  • [48] A Risk-Benefit Assessment of Tacrine in the Treatment of Alzheimer’s Disease
    Steven C. Samuels
    Kenneth L. Davis
    Drug Safety, 1997, 16 : 66 - 77
  • [49] A Risk-Benefit Assessment of Amifostine in Cytoprotection
    May Mabro
    Sandrine Faivre
    Eric Raymond
    Drug Safety, 1999, 21 : 367 - 387
  • [50] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    Drug Safety, 1998, 19 : 205 - 218
12345